GHRS
GH Research PLCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.42B
P/E Ratio
—
EPS
$-0.91
Beta
1.31
52W High
$25.94
52W Low
$11.32
50-Day MA
$20.19
200-Day MA
$15.78
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company at the forefront of developing psilocybin-based therapies for psychiatric and neurodegenerative disorders. The company boasts a robust pipeline aimed at addressing critical unmet needs in mental health care, driven by a highly experienced team committed to innovation in this rapidly evolving field. By pioneering groundbreaking therapeutic approaches, GH Research is well-positioned to redefine treatment paradigms and enhance patient outcomes, establishing itself as a potential leader in the mental health therapeutics market.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-66.58M |
| Operating Margin | 0.00% |
| Return on Equity | -19.70% |
| Return on Assets | -14.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.25 |
| Price-to-Book | 5.37 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -11.97 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $68.61M |
| Float | $26.72M |
| % Insiders | 24.23% |
| % Institutions | 70.22% |
Historical Volatility
HV 10-Day
62.13%
HV 20-Day
60.19%
HV 30-Day
57.63%
HV 60-Day
69.72%
HV Rank
17.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($39.50 target)
3
Strong Buy6
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026